- Home
- ASIC vs SYRE Comparison
ASIC vs SYRE Comparison
Compare ASIC & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASIC
- SYRE
- Stock Information
- Founded
- ASIC 2018
- SYRE 2013
- Country
- ASIC United States
- SYRE United States
- Employees
- ASIC N/A
- SYRE N/A
- Industry
- ASIC Property-Casualty Insurers
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- ASIC Finance
- SYRE Health Care
- Exchange
- ASIC Nasdaq
- SYRE Nasdaq
- Market Cap
- ASIC 1.1B
- SYRE 1.1B
- IPO Year
- ASIC 2025
- SYRE 2016
- Fundamental
- Price
- ASIC $21.00
- SYRE $15.65
- Analyst Decision
- ASIC Strong Buy
- SYRE Buy
- Analyst Count
- ASIC 4
- SYRE 5
- Target Price
- ASIC $27.00
- SYRE $55.00
- AVG Volume (30 Days)
- ASIC 73.5K
- SYRE 455.6K
- Earning Date
- ASIC 08-11-2025
- SYRE 11-06-2025
- Dividend Yield
- ASIC N/A
- SYRE N/A
- EPS Growth
- ASIC N/A
- SYRE N/A
- EPS
- ASIC 0.15
- SYRE N/A
- Revenue
- ASIC $378,302,000.00
- SYRE N/A
- Revenue This Year
- ASIC $16.14
- SYRE N/A
- Revenue Next Year
- ASIC $47.06
- SYRE N/A
- P/E Ratio
- ASIC $138.38
- SYRE N/A
- Revenue Growth
- ASIC 42.48
- SYRE N/A
- 52 Week Low
- ASIC $18.50
- SYRE $10.91
- 52 Week High
- ASIC $25.30
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- ASIC N/A
- SYRE 40.69
- Support Level
- ASIC N/A
- SYRE $15.80
- Resistance Level
- ASIC N/A
- SYRE $17.58
- Average True Range (ATR)
- ASIC 0.00
- SYRE 0.75
- MACD
- ASIC 0.00
- SYRE -0.12
- Stochastic Oscillator
- ASIC 0.00
- SYRE 0.52
About ASIC Ategrity Specialty Insurance Company Holdings Common Stock
Ategrity Specialty Insurance Co Holdings Formerly Ategrity Specialty Holdings LLC is a specialty insurance company dedicated to providing excess and surplus products to small to medium-sized businesses across the United States. It offers property and casualty insurance solutions tailored to meet the needs of SMBs. The company focuses on are Real Estate, Hospitality, Construction, and Retail.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.